The programme was developed to present to both clinicians and researchers the most up-to-date information on hereditary breast, ovarian and related cancers.

Upon completion of the programme the learner will be able to:

  • Be aware of resources that can help with variant interpretation;
  • Outline the latest developments in genetics and molecular science of hereditary breast and ovarian cancer;
  • Discriminate between clinically useful and less clinically useful breast cancer susceptibility gene tests;
  • Summarize new approaches to management of hereditary prostate and pancreas cancer risk;
  • Apply cutting edge science to manage persons at risk for, or who have developed, inherited forms of breast and/or ovarian cancer;
  • Evaluate in what circumstances polygenic risk scores may (or may not be) clinically useful;
  • Compare and contrast different methods of service delivery for hereditary breast/ovarian cancer;
  • Apply current data to develop reasonable cancer surveillance models for transgender and gender diverse people;
  • Recognize the existence of disparities in hereditary cancer genetics, and describe efforts to reduce inequality;
  • Identify and consider ethical issues surrounding population testing for breast and ovarian cancer risk.